NCT04447404View on ClinicalTrials.gov

DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury

PHASE2TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

March 4, 2021

Study Completion Date

March 4, 2021

Conditions

SARS-CoV-2

Interventions

DRUG

DUR-928

IV infusion

DRUG

Placebo

IV infusion

Trial Locations (1)

07103

Site 03, Newark

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Durect

INDUSTRY